Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharmaceutical Agrees To Settle Out Of Court with Novartis over Exelon (India)

This article was originally published in PharmAsia News

Executive Summary

Sun Pharmaceutical Industries agreed to an out-of-court settlement with Novartis over the Indian drug maker's efforts to market a generic of the Novartis drug Exelon (rivastigmine tartrate) for treating Alzheimer's disease. In doing so, Sun joins several other major Indian generics makers in agreeing to an out-of-court settlement with Novartis over Exelon. Sun won U.S. FDA fast-paced approval as the first generic to file, but it and Ranbaxy Laboratories and Dr. Reddy's, as well as U.S.-based Watson Pharmaceuticals, challenged the Novartis patent for Exelon and since reached settlements. Most of the settlements have allowed the generics to market their versions if the innovator gets a share. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel